RIPK4 was a critical molecule possessing high metastatic potential for PC patients characterized by high carcinoembryonic antigen (CEA) and cancer antigen 125-positive (CA125+)/CA19-9 levels. This evidence concerns the gene RIPK4 and pachyonychia congenita.